Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
November 6, 2008

Bristol-Myers Squibb Extends Research Collaboration with Exelixis

  • Exelixis will receive $6 million in additional funding with the one-year extension of its research collaboration with Bristol-Myers Squibb (BMS). The firms will now work together until January 12, 2010. The partnership focuses on therapies targeted against the Liver X Receptor, a nuclear hormone receptor implicated in cardiovascular and metabolic disorders.

    Under the terms of the original collaboration, the companies will identify drug candidates that are ready for IND-enabling studies. Bristol-Myers Squibb will undertake further preclinical and clinical development, regulatory activities, manufacturing, and sales/marketing operations for the compounds.

    The collaboration was established in January of 2006 for two years. Bristol-Myers Squibb previously extended the agreement through to January 12, 2009 in 2007.

  • You’re all set! Thank you for subscribing to GEN Highlights.